Publications by authors named "Peter Hirth"

Claim this Profile
R
RAF inhibitors that evade paradoxical MAPK pathway activation.
Chao Zhang, Wayne Spevak, Ying Zhang, Elizabeth A Burton, Yan Ma, Peter Hirth

Nature· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
William D Tap, Zev A Wainberg, Stephen P Anthony, Prabha N Ibrahim, Chao Zhang, Peter Hirth

N Engl J Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.
Chao Zhang, Prabha N Ibrahim, Jiazhong Zhang, Elizabeth A Burton, Gaston Habets, Peter Hirth

Proc Natl Acad Sci U S A· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vemurafenib: the first drug approved for BRAF-mutant cancer.
Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha Ibrahim, Peter Hirth

Nat Rev Drug Discov· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
Bjoern Buchholz, Bernd Klanke, Gunnar Schley, Gideon Bollag, James Tsai, Peter Hirth

Nephrol Dial Transplant· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N Ibrahim

Nature· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
William D Tap, Ke-Wei Gong, Judy Dering, Yiou Tseng, Charles Ginther, Peter Hirth

Neoplasia· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
Dean R Artis, Jack J Lin, Chao Zhang, Weiru Wang, Upasana Mehra, K Peter Hirth

Proc Natl Acad Sci U S A· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
James Tsai, John T Lee, Weiru Wang, Jiazhong Zhang, Hanna Cho, Peter Hirth

Proc Natl Acad Sci U S A· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The science-business tango. Interview by Mari Paul.
Peter Hirth

Nat Biotechnol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.
Laimute Taraseviciene-Stewart, Lajos Gera, Peter Hirth, Norbert F Voelkel, Rubin M Tuder

Can J Physiol Pharmacol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis